PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 2470758-9 1989 These intermediates most closely resembled either native alpha 2M or the well established "H" structure of alpha 2M-proteinase, depending on the initial conditions used to modify the alpha 2 M with cis-DDP. Cisplatin 198-205 alpha-2-macroglobulin Homo sapiens 183-192 8636430-0 1996 Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. Cisplatin 23-55 alpha-2-macroglobulin Homo sapiens 66-87 8636430-0 1996 Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. Cisplatin 23-55 alpha-2-macroglobulin Homo sapiens 89-97 8636430-0 1996 Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. Cisplatin 23-55 alpha-2-macroglobulin Homo sapiens 157-165 8636430-0 1996 Altered interaction of Cis-dichlorodiammineplatinum(II)--modified alpha 2-macroglobulin (alpha 2M) with the low density lipoprotein receptor-related protein/alpha 2M receptor but not the alpha 2M signaling receptor. Cisplatin 23-55 alpha-2-macroglobulin Homo sapiens 157-165 8636430-4 1996 We also demonstrate that chemical modification of alpha 2M* with cis-dichlorodiammineplatinum (cis-DDP) does not significantly alter binding to either receptor or signaling characteristics as compared with unmodified alpha 2M*. Cisplatin 65-93 alpha-2-macroglobulin Homo sapiens 50-58 8636430-4 1996 We also demonstrate that chemical modification of alpha 2M* with cis-dichlorodiammineplatinum (cis-DDP) does not significantly alter binding to either receptor or signaling characteristics as compared with unmodified alpha 2M*. Cisplatin 65-93 alpha-2-macroglobulin Homo sapiens 50-59 2470758-0 1989 Electron microscopy studies of alpha 2-macroglobulin conformational intermediates obtained by derivatization with cis-dichlorodiammineplatinum (II). Cisplatin 114-142 alpha-2-macroglobulin Homo sapiens 31-52 2470758-1 1989 The structure of human alpha 2-macroglobulin (alpha 2M) after reaction with cis-dichlorodiammineplatinum (II) (cis-DDP) was studied by electron microscopy. Cisplatin 76-109 alpha-2-macroglobulin Homo sapiens 23-44 2470758-1 1989 The structure of human alpha 2-macroglobulin (alpha 2M) after reaction with cis-dichlorodiammineplatinum (II) (cis-DDP) was studied by electron microscopy. Cisplatin 76-109 alpha-2-macroglobulin Homo sapiens 46-54 2470758-1 1989 The structure of human alpha 2-macroglobulin (alpha 2M) after reaction with cis-dichlorodiammineplatinum (II) (cis-DDP) was studied by electron microscopy. Cisplatin 111-118 alpha-2-macroglobulin Homo sapiens 23-44 2470758-1 1989 The structure of human alpha 2-macroglobulin (alpha 2M) after reaction with cis-dichlorodiammineplatinum (II) (cis-DDP) was studied by electron microscopy. Cisplatin 111-118 alpha-2-macroglobulin Homo sapiens 46-54 2470758-7 1989 The cis-DDP prevented complete conformational change when the alpha 2M was reacted with trypsin. Cisplatin 4-11 alpha-2-macroglobulin Homo sapiens 62-70 2470758-9 1989 These intermediates most closely resembled either native alpha 2M or the well established "H" structure of alpha 2M-proteinase, depending on the initial conditions used to modify the alpha 2 M with cis-DDP. Cisplatin 198-205 alpha-2-macroglobulin Homo sapiens 107-115 2482066-0 1989 Independent analysis of bait region cleavage dependent and thiolester bond cleavage dependent conformational changes by cross-linking of alpha 2-macroglobulin with cis-dichlorodiammineplatinum(II) and dithiobis(succinimidyl propionate). Cisplatin 164-192 alpha-2-macroglobulin Homo sapiens 137-158 2482066-2 1989 Previous studies from this laboratory have shown that cross-linking the alpha 2M subunits with cis-dichlorodiammineplatinum(II) (cis-DDP) prevents the proteinase-induced conformational changes which lead to the activation and cleavage of the internal thiolester bonds of alpha 2M. Cisplatin 95-127 alpha-2-macroglobulin Homo sapiens 72-80 2482066-2 1989 Previous studies from this laboratory have shown that cross-linking the alpha 2M subunits with cis-dichlorodiammineplatinum(II) (cis-DDP) prevents the proteinase-induced conformational changes which lead to the activation and cleavage of the internal thiolester bonds of alpha 2M. Cisplatin 95-127 alpha-2-macroglobulin Homo sapiens 271-279 2482066-2 1989 Previous studies from this laboratory have shown that cross-linking the alpha 2M subunits with cis-dichlorodiammineplatinum(II) (cis-DDP) prevents the proteinase-induced conformational changes which lead to the activation and cleavage of the internal thiolester bonds of alpha 2M. Cisplatin 129-136 alpha-2-macroglobulin Homo sapiens 72-80 2482066-2 1989 Previous studies from this laboratory have shown that cross-linking the alpha 2M subunits with cis-dichlorodiammineplatinum(II) (cis-DDP) prevents the proteinase-induced conformational changes which lead to the activation and cleavage of the internal thiolester bonds of alpha 2M. Cisplatin 129-136 alpha-2-macroglobulin Homo sapiens 271-279 2482066-3 1989 In addition, cis-DDP treatment prevents the proteinase- or CH3NH2-induced conformational changes in alpha 2M which lead to a "slow" to "fast" change in nondenaturing polyacrylamide gel electrophoresis. Cisplatin 13-20 alpha-2-macroglobulin Homo sapiens 100-108 2470758-10 1989 When cis-DDP-treated alpha 2M was reacted with trypsin, purified by chromatography and subsequently treated with diethyldithiocarbamate, complete conformational change was observed. Cisplatin 5-12 alpha-2-macroglobulin Homo sapiens 21-29 2452164-6 1988 alpha 2M is known to possess a methionyl residue which is susceptible to modification by cis-dichlorodiammineplatinum (II) (cis-DDP) with the result being a loss of receptor binding ability by alpha 2M. Cisplatin 89-122 alpha-2-macroglobulin Homo sapiens 0-8 2452164-6 1988 alpha 2M is known to possess a methionyl residue which is susceptible to modification by cis-dichlorodiammineplatinum (II) (cis-DDP) with the result being a loss of receptor binding ability by alpha 2M. Cisplatin 89-122 alpha-2-macroglobulin Homo sapiens 193-201 2452164-6 1988 alpha 2M is known to possess a methionyl residue which is susceptible to modification by cis-dichlorodiammineplatinum (II) (cis-DDP) with the result being a loss of receptor binding ability by alpha 2M. Cisplatin 124-131 alpha-2-macroglobulin Homo sapiens 0-8 2452164-6 1988 alpha 2M is known to possess a methionyl residue which is susceptible to modification by cis-dichlorodiammineplatinum (II) (cis-DDP) with the result being a loss of receptor binding ability by alpha 2M. Cisplatin 124-131 alpha-2-macroglobulin Homo sapiens 193-201 2450578-0 1988 Intersubunit cross-linking by cis-dichlorodiammineplatinum(II) stabilizes an alpha 2-macroglobulin "nascent" state: evidence that thiol ester bond cleavage correlates with receptor recognition site exposure. Cisplatin 30-58 alpha-2-macroglobulin Homo sapiens 77-98 2450578-3 1988 cis-Dichlorodiammineplatinum(II) (cis-DDP) causes extensive intersubunit cross-linking of alpha 2M. Cisplatin 0-28 alpha-2-macroglobulin Homo sapiens 90-98 2450578-3 1988 cis-Dichlorodiammineplatinum(II) (cis-DDP) causes extensive intersubunit cross-linking of alpha 2M. Cisplatin 34-41 alpha-2-macroglobulin Homo sapiens 90-98 2450578-4 1988 Incubation of alpha 2M or cis-DDP-treated alpha 2M with trypsin results in complete subunit cleavage; however, trypsin treatment of cis-DDP-alpha 2M does not result in a conformational change as determined by nondenaturing polyacrylamide gel electrophoresis (PAGE), receptor recognition site exposure, or appearance of thiol groups from the inhibitor. Cisplatin 26-33 alpha-2-macroglobulin Homo sapiens 42-50 2450578-4 1988 Incubation of alpha 2M or cis-DDP-treated alpha 2M with trypsin results in complete subunit cleavage; however, trypsin treatment of cis-DDP-alpha 2M does not result in a conformational change as determined by nondenaturing polyacrylamide gel electrophoresis (PAGE), receptor recognition site exposure, or appearance of thiol groups from the inhibitor. Cisplatin 26-33 alpha-2-macroglobulin Homo sapiens 42-50 2450578-5 1988 These results are in marked contrast to previous studies which demonstrated that incubation of cis-DDP-treated alpha 2M with CH3NH2 resulted in thiol ester bond cleavage and receptor recognition site exposure. Cisplatin 95-102 alpha-2-macroglobulin Homo sapiens 111-119 2450578-6 1988 cis-DDP-treated alpha 2M bound only 0.13 mol of 125I-trypsin/mol of cis-DDP-alpha 2M. Cisplatin 0-7 alpha-2-macroglobulin Homo sapiens 16-24 2450578-6 1988 cis-DDP-treated alpha 2M bound only 0.13 mol of 125I-trypsin/mol of cis-DDP-alpha 2M. Cisplatin 0-7 alpha-2-macroglobulin Homo sapiens 76-84 2450578-6 1988 cis-DDP-treated alpha 2M bound only 0.13 mol of 125I-trypsin/mol of cis-DDP-alpha 2M. Cisplatin 68-75 alpha-2-macroglobulin Homo sapiens 16-24 2450578-6 1988 cis-DDP-treated alpha 2M bound only 0.13 mol of 125I-trypsin/mol of cis-DDP-alpha 2M. Cisplatin 68-75 alpha-2-macroglobulin Homo sapiens 76-84 2450578-9 1988 These results demonstrate that cross-linking of alpha 2M by cis-DDP prevents a conformational change in the inhibitor which is necessary for thiol ester bond activation and cleavage. Cisplatin 60-67 alpha-2-macroglobulin Homo sapiens 48-56 3026342-1 1986 alpha 2-Macroglobulin (alpha 2M)-methylamine that had been allowed to react with cis-dichlorodiammineplatinum(II) (cis-DDP) bound with greatly reduced affinity to specific alpha 2M receptors, as determined by macrophage binding studies in vitro and plasma-clearance experiments in vivo. Cisplatin 81-109 alpha-2-macroglobulin Homo sapiens 0-21 3026342-16 1986 It is concluded that cis-DDP and H2O2 modify a critical methionine residue in the primary sequence of the alpha 2M-receptor recognition site. Cisplatin 21-28 alpha-2-macroglobulin Homo sapiens 106-114 3026342-1 1986 alpha 2-Macroglobulin (alpha 2M)-methylamine that had been allowed to react with cis-dichlorodiammineplatinum(II) (cis-DDP) bound with greatly reduced affinity to specific alpha 2M receptors, as determined by macrophage binding studies in vitro and plasma-clearance experiments in vivo. Cisplatin 81-109 alpha-2-macroglobulin Homo sapiens 23-31 3026342-1 1986 alpha 2-Macroglobulin (alpha 2M)-methylamine that had been allowed to react with cis-dichlorodiammineplatinum(II) (cis-DDP) bound with greatly reduced affinity to specific alpha 2M receptors, as determined by macrophage binding studies in vitro and plasma-clearance experiments in vivo. Cisplatin 115-122 alpha-2-macroglobulin Homo sapiens 0-21 3026342-1 1986 alpha 2-Macroglobulin (alpha 2M)-methylamine that had been allowed to react with cis-dichlorodiammineplatinum(II) (cis-DDP) bound with greatly reduced affinity to specific alpha 2M receptors, as determined by macrophage binding studies in vitro and plasma-clearance experiments in vivo. Cisplatin 115-122 alpha-2-macroglobulin Homo sapiens 23-31 3026342-1 1986 alpha 2-Macroglobulin (alpha 2M)-methylamine that had been allowed to react with cis-dichlorodiammineplatinum(II) (cis-DDP) bound with greatly reduced affinity to specific alpha 2M receptors, as determined by macrophage binding studies in vitro and plasma-clearance experiments in vivo. Cisplatin 115-122 alpha-2-macroglobulin Homo sapiens 172-180 3026342-6 1986 alpha 2M-methylamine was affected significantly less by the H2O2 exposure after pretreatment with cis-DDP. Cisplatin 98-105 alpha-2-macroglobulin Homo sapiens 0-8 6209003-4 1984 alpha 2-Macroglobulin lost 90% of its activity and was completely cross-linked, as determined with polyacrylamide gel electrophoresis, after reaction with cisplatin (0.6 to 1.0 mM). Cisplatin 155-164 alpha-2-macroglobulin Homo sapiens 0-21 6209003-7 1984 Only KCN was comparably effective as an inhibitor of the reaction of cisplatin with alpha 2-macroglobulin; however, KCN was significantly less reactive with preformed platinum(II)-protein bonds than was diethyldithiocarbamate. Cisplatin 69-78 alpha-2-macroglobulin Homo sapiens 84-105 28969563-4 2018 Platinum drug-cisplatin interacts covalently and alters the function of the key plasma protease inhibitor molecule -alpha-2-macroglobulin and induces the conformational changes in the protein molecule and inactivates it. Cisplatin 14-23 alpha-2-macroglobulin Homo sapiens 116-137 6209003-0 1984 Effects of diethyldithiocarbamate and nine other nucleophiles on the intersubunit protein cross-linking and inactivation of purified human alpha 2-macroglobulin by cis-diamminedichloroplatinum(II). Cisplatin 164-192 alpha-2-macroglobulin Homo sapiens 139-160 6209003-1 1984 The cross-linking and inactivation of the plasma protein alpha 2-macroglobulin by cis-diamminedichloroplatinum(II) (cisplatin; Gonias, S. L., and Pizzo, S. V. J. Biol. Cisplatin 82-113 alpha-2-macroglobulin Homo sapiens 57-78 6209003-1 1984 The cross-linking and inactivation of the plasma protein alpha 2-macroglobulin by cis-diamminedichloroplatinum(II) (cisplatin; Gonias, S. L., and Pizzo, S. V. J. Biol. Cisplatin 116-125 alpha-2-macroglobulin Homo sapiens 57-78 29751037-0 2018 Interaction of anti-cancer drug-cisplatin with major proteinase inhibitor-alpha-2-macroglobulin: Biophysical and thermodynamic analysis. Cisplatin 32-41 alpha-2-macroglobulin Homo sapiens 74-95 29751037-1 2018 Alpha-2-macroglobulin is a multifunctional, highly abundant, plasma protein which reacts with a wide variety of molecules and drugs including cisplatin. Cisplatin 142-151 alpha-2-macroglobulin Homo sapiens 0-21 29751037-3 2018 This study is designed to examine the interaction of cisplatin with human alpha-2-macroglobulin through various biophysical techniques and drug binding through molecular modeling. Cisplatin 53-62 alpha-2-macroglobulin Homo sapiens 74-95 29751037-4 2018 Cisplatin alters the function of alpha-2-macroglobulin and the thiolesters are most likely the reactive sites for cisplatin. Cisplatin 0-9 alpha-2-macroglobulin Homo sapiens 33-54 29751037-4 2018 Cisplatin alters the function of alpha-2-macroglobulin and the thiolesters are most likely the reactive sites for cisplatin. Cisplatin 114-123 alpha-2-macroglobulin Homo sapiens 33-54 29751037-5 2018 Our result suggests that cisplatin decreases the antiproteolytic potential and causes structural and functional change in human alpha-2-macroglobulin as evident by absorption and fluorescence spectroscopy. Cisplatin 25-34 alpha-2-macroglobulin Homo sapiens 128-149 29751037-7 2018 Thermodynamics parameters such as entropy (DeltaS), enthalpy (DeltaH) and Gibb"s free energy changes (DeltaG) along with number of binding sites (N) of alpha-2-macroglobulin-cisplatin binding in solutions were determined by isothermal titration calorimetry (ITC). Cisplatin 174-183 alpha-2-macroglobulin Homo sapiens 152-173 29751037-8 2018 It was found that binding of cisplatin with alpha-2-macroglobulin was exothermic in nature. Cisplatin 29-38 alpha-2-macroglobulin Homo sapiens 44-65